Boston Scientific Corp

• Wall Street upgrades and UBS ratings changes drove Illumina stock upward. • Illumina will rejoin the S&P 500 index during rebalancing. • Annual revenue reached $4.34 billion with a net profit of $850 million.

• Natera reported strong adoption for Signatera and positive Medicare reimbursement updates. • The company achieved robust top-line revenue growth with $2.31B annual revenue. • Analysts issued Buy ratings with an average price target of $342.35.

• UBS upgraded Illumina to Buy with a price target of $260. • Illumina will rejoin the S&P 500 index from the S&P MidCap 400. • The company reported strong NovaSeq X demand and consecutive earnings beats.

• Cooper Companies missed revenue expectations and lowered its fiscal guidance. • The board decided to retain the CooperSurgical business. • Multiple analysts downgraded the stock following negative market reactions.

• Elevance Health reported third-quarter adjusted earnings tracking above previous guidance. • Management projects double-digit earnings growth driven by healthcare segment expansion. • ELV shows a MACD buy signal with an RSI of 60.937.

• Intuitive Surgical faced selling pressure from moderated domestic elective procedure growth. • Rising competition from rival medical robotic systems created investor sentiment drag. • Premium valuation multiples and insider stock sales compounded recent downside momentum.